Angiogenesis is the complex process by which new blood vessels arise from preexisting vasculature. The development of a vascular supply is essential not only for organ development and differentiation during embryogenesis but also for wound healing and reproductive functions in the adult. Dysregulation of angiogenesis, however, contributes to several pathological conditions, such as diabetic retinopathy, rheumatoid arthritis, and solid tumor development (1 ) . Although recent evidence indicates that new vessel growth and maturation are highly complex and coordinated processes, vascular endothelial growth factor (VEGF) 4 signaling is generally agreed to be a crucial step for the regulation of angiogenesis (2 ) .
VEGF is a highly specific mitogen for endothelial cells, inducing angiogenesis as well as the permeabilization of blood vessels and playing a central role in the regulation of vasculogenesis (2 ) . Through alternative splicing of a single VEGF gene, various isoforms are produced. To date 7 VEGF splice variants have been reported, ranging in length from 121 to 206 amino acids (3) (4) (5) (6) (7) . All splice variants contain exons 1-5 and 8 and differ only by various combinations of either no additional exon [VEGF 121 (3 ) ] or addition of exon 6 [VEGF 145 (4 ) ], exon 7 [VEGF 165 (3 ) ], exons 6 and 7 [VEGF 189 (3 ) ], or exons 6, 6Ј, and 7 [VEGF 206 (5 ) ]. VEGF 148 has the same amino acid sequence as VEGF 165 , apart from a 35-bp-long deletion at the end of exon 7 (6 ) , whereas in VEGF 183 the final 18 bp of exon 6a are missing (7 ) . An important biological property that differentiates the various VEGF isoforms is the sulfate-binding capacity of heparin and heparan. VEGF 121 does not bind to heparin and is a freely soluble protein; VEGF 165 is also secreted, although a significant fraction remains bound to the cell surface and the extracellular matrix. In contrast, VEGF 189 and VEGF 206 are almost completely sequestered in the extracellular matrix because of their high binding affinity for heparin (1, 2, 8 ) . VEGF splice variants bind to 2 tyrosine-kinase receptors, VEGF receptor 1 (VEGFR-1; flt-1) and VEGFR-2 (KDR/ flk-1), and 2 isoform-specific receptors, neurophilin-1 and neurophilin-2, which bind to VEGF 165 but not VEGF 121 (9 ) . One soluble receptor, sVEGFR-1, created by alternative splicing of VEGFR-1, was reported to act as a competitive antagonist to VEGF (10 ) . Most cell types produce several VEGF variants simultaneously. Usually VEGF 121 and VEGF 165 are the predominant forms, followed by VEGF 189 (3 ) . VEGF 183 also has wide tissue distribution and may have gone undetected because of confusion with VEGF 189 (7 ) . In contrast, VEGF 145 , VEGF 148 , and VEGF 206 are comparatively rare and detected in trace amounts (4 -6, 11 ) .
The expression of VEGF splice variants has been investigated in various neoplasms, but current data are contradictory (12) (13) (14) (15) (16) (17) (18) . The increased expression of VEGF 165 and VEGF 189 in osteosarcoma (12 ) , renal cell carcinoma (13 ) , non-small cell lung cancer (NSCLC) (14 -16 ) , and colon cancer (17 ) was correlated with neovascularization, tumor progression, and poor prognosis. On the other hand, another study reported no relation of VEGF isoform patterns with invasion and progression in breast and ovarian cancer (18 ) . In most studies, semiquantitative techniques such as conventional reverse transcription-PCR (RT-PCR) were used to determine the expression of VEGF splice variants, and only malignant tissues and not pairs of cancerous and healthy tissues were investigated. We recently developed a real-time RT-PCR method for the quantification of mRNA of individual VEGF splice variants (11 ) . In the present study, we used this method to quantify the expression of total VEGF and 4 VEGF splicevariant mRNA (VEGF 121 , VEGF 165 , VEGF 183 , and VEGF 189 ) in pairs of cancerous and adjacent noncancerous tissues originating from patients with NSCLC. In addition, we developed a similar real-time RT-PCR approach to quantify the expression of VEGFRs, VEGFR-1 and VEGFR-2, in the same tissue pairs. The purpose of our study was to apply this highly sensitive and accurate technique to evaluate possible correlations between the expression pattern of VEGF splice variants and the clinicopathological characteristics of tumors and possible differences in VEGF splice-variant expression patterns in malignant vs healthy tissues.
Materials and Methods selection of patients
Lung carcinoma and adjacent nonneoplastic tissues were obtained sequentially from 27 male NSCLC patients. All patients and donors gave their informed consent, and the study was approved by the ethics and scientific committees of the participating institutions. The tumor types and stages were determined according to the WHO classification. Tissue samples were immediately flash frozen in liquid nitrogen and stored at Ϫ80°C until use. All samples were analyzed histologically to assess the amount of tumor component (at least 70% of tumor cells) and the quality of material (i.e., absence of necrosis). The clinicopathological characteristics of the tumors investigated are summarized in Table 1 .
rna isolation and cDNA synthesis
We isolated total cellular RNA with the Qiagen RNeasy Mini Reagent Set (Qiagen) according to the manufacturer's instructions. All preparation and handling of RNA took place in a laminar flow hood, under RNase-free conditions, and the isolated RNA was stored at Ϫ70°C until used. RNA concentration was determined with a NanoDrop ND-100 spectrophotometer (NanoDrop Technologies). Reverse transcription of RNA was carried out with the ImProm II Reverse Transcription System (Promega) according to the manufacturer's instructions, using 1 g of total RNA as template. RNA integrity of the cDNA preparations was tested by real-time PCR amplification of the porphobilinogen deaminase housekeeping gene hydroxymethylbilane synthase (HMBS). 5 
real-time rt-pcr
Real-time RT-PCR for the quantification of total VEGF and 4 VEGF splice variants (VEGF 121 , VEGF 165 , VEGF 183 , and VEGF 189 ) was performed as previously described (11 ) . For the quantification of VEGFRs, specific primers 5 Human gene: HMBS, hydroxymethylbilane synthase. and probes were designed with the Primer Premier software. To prevent amplification of genomic DNA, the oligonucleotides designed were intron spanning. VEGFR-1 primers are located in an area present in both membrane-associated and soluble receptors and can therefore amplify both forms of VEGFR-1. The sequences of the primers and probes for VEGFRs are presented in Table 2 . For the quantification of both VEGFRs the cycling protocol consisted of an initial 5-min denaturation step at 95°C, followed by 45 cycles of denaturation at 95°C for 10 s and annealing/extension at 60°C for 1 min. 
Results
We investigated the expression of total VEGF, VEGF splice variants, and VEGFRs in 27 paired samples of tumor specimens and adjacent healthy tissue. Our results were normalized to the amount of total RNA present in each sample and are expressed as copy number of the gene of interest per micrograms of total RNA. All specimens investigated (healthy and malignant) expressed total VEGF. The expression of all genes investigated is presented in Table 3 . Total VEGF mRNA expression was found to be significantly higher in tumor samples than in their corresponding adjacent healthy tissue (P Ͻ0.01; Table 3 ; Fig. 1 ), and the same applied for the splice variants VEGF 121 and VEGF 165 (P Ͻ0.01 and P ϭ 0.01, respectively; Table 3 ; Fig.  2, A and B) . On the other hand, VEGF 183 and VEGF 189 displayed higher expression in healthy tissues than in their corresponding malignant tissues (Table 3 ; Fig. 2 , C and D), but this trend did not reach statistical significance (P ϭ 0.08 and 0.11, respectively). The expression of both VEGFRs, VEGFR-1 and VEGFR-2, was similar between paired specimens (Table 3 ; Fig. 2, E and F) . We observed significant correlations between the expression of total VEGF and all 4 VEGF splice variants as well as between all 4 VEGF splice variants in both healthy and malignant tissues (P Ͻ0.01 in all cases). We also observed strong linear relationships between total VEGF or VEGF splice variants and VEGFR-1 in normal lung tissues (P Ͻ0.01 in all cases), whereas in malignant samples a linear relationship existed only between VEGF 189 and VEGFR-1 expression (P Ͻ0.01). The expression of total VEGF, VEGF 121 , and VEGF 165 correlated significantly with the expression of VEGFR-2 in normal lung tissue (P Ͻ0.01 in all cases); in cancerous tissues, however, a linear relationship existed between total VEGF or VEGF 121 and VEGFR-2 (P ϭ 0.04 in both cases).
We also examined the relative expression (%) of VEGF splice variants, i.e., the ratio of a specific variant to the sum of all VEGF splice variants (copy number:micrograms total RNA) in healthy and malignant tissues. We Fig. 3) ].
We did not find any correlation between total VEGF, VEGF splice variants, or VEGFRs expression and age or tumor size. Also, the expression of total VEGF and VEGF splice variants and relative expression of the variants did not differ between adenocarcinoma specimens and squamous cell carcinoma specimens; the same applied for VEGFR-1 and VEGFR-2. We observed, however, that the expression of total VEGF tended to be higher in tumor specimens originating from lymph-node-positive than lymph-node-negative patients, although the difference did not reach statistical significance. The expression of the investigated genes did not differ depending on tumor stage (I/II vs III/IV).
Discussion
VEGF is a potent angiogenic factor, and its expression has been studied in both mRNA and protein in many different tumors. VEGF upregulation is reported in a wide variety of cancer cells and was associated with a poor prognosis in patients with breast, colon, renal, and lung carcinomas (13, 16 -23 ) . The presence of various isoforms deriving from alternative splicing of a single VEGF gene has been reported, and some studies have shown that the expression of certain splice variants is related to tumor progression (12, 14, 15 ) . Current data are contradictory, however, and further studies are required to elucidate the biological role of VEGF splice variants. Most studies have investigated VEGF protein expression in lung carcinomas using immunohistochemical staining; only a few studies have examined VEGF expression at the transcriptional level. Usually RT-PCR, a semiquantitative technique, is used, and only the variants VEGF 121 , VEGF 165 , and VEGF 189 are investigated. In the present study we used real-time RT-PCR, which is a more sensitive and accurate technique, for the quantification in pairs of malignant and adjacent normal lung tissues of mRNA for total VEGF, 4 VEGF splice variants (VEGF 121 , VEGF 165 , VEGF 183 , and VEGF 189 ), and 2 VEGFRs (VEGFR-1 and VEGFR-2). Although VEGF 183 has wide tissue distribution and was detected in cancer and ovarian cell lines, to our knowledge this investigation is the first to detect VEGF 183 in lung tissue. We did not include the variants VEGF 145 , VEGF 148 , or VEGF 206 in our study, because they are expressed in trace amounts and seem to be of minor importance. The primary VEGF transcript derives from a single gene, and various isoforms are produced through alternative splicing. Although the precise biological role of VEGF isoforms remains unclear, it is believed that individual VEGF isoforms mediate different aspects of vascular growth. This concept is supported by the fact that different VEGF isoforms exhibit different binding affinities toward heparin sulfate and thus differ in extracellular localization and accessibility (1, 2 ) . VEGF isoforms are not functionally equivalent; previous studies have shown that the presence of all isoforms is required for normal vascular development (14 ) . Moreover, examination of mRNA in VEGF splice variants 121, 165, and 189 revealed that the relative amounts of VEGF splice variants varied among different organs and that their expression patterns changed during organ development (24, 25 ) . In agreement with these findings, we report that the expression profile of VEGF splice variants varies between malignant and healthy lung tissues. In both cases VEGF 121 is the major variant expressed, but its percentage as part of the total VEGF message is significantly enhanced in tumor specimens. VEGF 121 is the predominant splice variant expressed in various carcinomas and is considered to be more strongly tumorigenic than the other splice variants in vivo (26 ) . Although the ratio of VEGF 165 to total VEGF was similar between matched specimens, the ratios of VEGF 183 and VEGF 189 were downregulated in lung carcinomas. Total VEGF mRNA showed significantly higher expression in cancer tissues than in paired adjacent normal lung tissues. The analysis of mRNA expression in VEGF splice variants revealed overexpression of VEGF 121 and VEGF 165 and lower expression of VEGF 183 and VEGF 189 in all NSCLC tumor samples compared with their corresponding noncancerous specimens. These results are in keeping with the findings of a recent study (27 ) . Our data indicate that overexpression of VEGF in lung tumors is caused by the most diffusible variants and supports the observation that during malignant progression an angiogenic switch occurs and favors the shorter diffusible isoforms (28 ) .
We did not find any correlation between the expression of total VEGF or VEGF splice variants and clinicopathological characteristics of the tumors investigated. We observed that lymph-node-positive tumors overexpressed total VEGF, although this tendency did not reach statistical significance, but found no differences in the expression profiles of VEGF splice variants. Previous studies have reported that VEGF expression is associated with nodal involvement in NSCLC (16, 20 ) . Biological behavior differs between the 2 main histological types of NSCLC: adenocarcinoma has a higher metastatic potential than squamous cell carcinomas (16 ) . Some studies report that VEGF expression is higher in adenocarcinomas than squamous cell carcinomas (16, 21 ) , but data also suggest that there is no difference in VEGF levels between those 2 subtypes (29, 30 ) . We observed that the 2 histological types of NSCLC not only displayed similar expression of VEGF and VEGF splice variants, but also showed similar relative expression of VEGF splice variants, and therefore we conclude that their different metastatic potential cannot be associated with VEGF.
Discrepancies between our results and the results of previous studies can be attributed to the use of different methods for the quantification of VEGF and, in cases when RT-PCR is used, to the housekeeping gene selected for the normalization of results. A number of different genes are used as internal controls for qualitative RT-PCR analyses since their expression is assumed to be constant at different times and after many forms of experimental manipulations. However, a recent study reported a high interindividual variability of control gene RNAs in breast and colon biopsies and significant differences in intraindividual RNA levels between paired normal and cancer specimens (31 ) . For this reason, we did not use a housekeeping gene, but our results were normalized to the amount of total RNA present in each sample as previously described (11 ) . The validity of this approach has been confirmed, since normalization of VEGF mRNA expression to total RNA in breast cancer biopsies correlated well with protein levels, and VEGF mRNA expression levels were found augmented in comparison with paired normal tissues (31 ) . On the other hand, normalization of VEGF mRNA to various housekeeping genes generated confusing and misleading results that were contradicted by protein quantification. VEGF mRNA levels could be made to appear increased, decreased, or unchanged between matched samples depending on the normalizer chosen (31 ).
In conclusion, our study shows for the first time the splice variant profile of VEGF in a quantitative aspect in NSCLC. Our study has revealed a different VRGF splicing variant expression profile in NSCLC in respect to nonmalignant paired tissues. More specifically, our results show that absolute expression, as well as the expression pattern of certain VEGF splice variants, is altered during tumorigenesis and support the hypothesis that during malignant progression an angiogenic switch favoring the shorter diffusible isoforms occurs. The low number of specimens studied constitutes a limitation for the detection of significant associations between isoform or receptor expression and clinical prognostic variables. It would be of interest to extend this study in a larger number of clinical samples and different cancers, since most studies so far are based on the expression of total VEGF. Taking into account the great importance of VEGF in cancer, as a specific molecular target of very recently approved angiogenesis-based novel cancer therapeutics (AVASTIN, Roche), we strongly believe that our results will be of importance for clinical researchers who will design clinical studies to evaluate the response to VEGF-based therapy in a larger number of patients. 
